Karen Reckamp
Overview
Explore the profile of Karen Reckamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Davelaar J, Gaddam S, Kosari K, Nissen N, Chaux G, et al.
J Natl Compr Canc Netw
. 2022 Nov;
21(1):6-11.
PMID: 36395704
Pancreatic metastasis of primary lung adenocarcinoma is a rare occurrence, accounting for <0.3% of all pancreatic malignancies. Given that the prognosis and treatment options for primary pancreatic cancer differ greatly...
2.
Datta G, Lauzon M, Salvy S, Hussain S, Ghandehari S, Merchant A, et al.
Front Public Health
. 2022 Apr;
10:801805.
PMID: 35372243
The COVID-19 pandemic has the potential to impact long-standing efforts to increase adherence to cancer screening guidelines. Healthcare workers (HCWs) experienced significant hardship, but generally have greater access to preventive...
3.
Wing S, Hu H, Lopez L, Solomon I, Shen J, Raquel C, et al.
Oncologist
. 2021 Aug;
26(12):e2302-e2305.
PMID: 34355454
Background: Genomic testing of somatic and germline DNA has transformed cancer care. However, low genetic knowledge among patients may compromise care and health outcomes. Given the rise in genomic testing,...
4.
Liu B, Duenas D, Zheng L, Reckamp K, Shen B
Protein Cell
. 2021 Jul;
13(2):82-89.
PMID: 34319535
No abstract available.
5.
Do K, Chow L, Reckamp K, Sanborn R, Burris H, Robert F, et al.
Oncologist
. 2021 Jul;
26(11):925-e1918.
PMID: 34288257
Lessons Learned: Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy for treating a broad range of cancers. In this first-in-human,...
6.
Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, et al.
J Thorac Dis
. 2020 Nov;
12(9):5086-5095.
PMID: 33145085
Background: mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In...
7.
Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz A, Hozo I, et al.
JCO Oncol Pract
. 2020 Jul;
17(2):e257-e265.
PMID: 32639928
Purpose: Omic-informed therapy is being used more frequently for patients with non-small-cell lung cancer (NSCLC) being treated on the basis of evidence-based decision-making. However, there is a lack of a...
8.
Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, et al.
Lung Cancer
. 2020 Jun;
146:174-181.
PMID: 32554069
Objectives: Immune checkpoint inhibitors (ICIs) have changed the landscape of lung cancer therapy. However significant proportions of patients have primary or acquired resistance to ICIs. Molecular characterization is critical for...
9.
Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, et al.
PLoS One
. 2020 Feb;
15(2):e0228188.
PMID: 32045431
Objectives: Oncology has become more reliant on new testing methods and a greater use of electronic medical records, which provide a plethora of information available to physicians and researchers. However,...
10.
Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, et al.
Am J Clin Oncol
. 2019 Feb;
42(4):337-344.
PMID: 30741758
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in about 4% to 8% non-small cell lung cancer (NSCLC). ALK+ tumors have been associated with increased pleural and pericardial disease....